Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 4:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Candida Clear all
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome

NCT02996448
View directory record Official record
Conditions
Autosomal-dominant Hyper-IgE Syndrome
Interventions
NDV-3A
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Sep 4, 2026, 4:43 PM EDT
Completed Phase 4 Interventional Results available

Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants

NCT00702507
View directory record Official record
Conditions
Diaper Rash
Interventions
0.25 % Miconazole Nitrate Ointment
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
Up to 15 Months
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
5
States / cities
San Diego, California • Coral Gables, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2012 · Synced Sep 4, 2026, 4:43 PM EDT
Completed Phase 3 Interventional

Candin for the Treatment of Common Warts

NCT05889845
View directory record Official record
Conditions
Common Warts (Verruca Vulgaris)
Interventions
Candin, Intradermal Solution, Placebo
Drug
Lead sponsor
Nielsen BioSciences, Inc.
Industry
Eligibility
12 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
18
States / cities
Birmingham, Alabama • Bryant, Arkansas • Fort Smith, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 4, 2026, 4:43 PM EDT
Completed Phase 1 Interventional

An Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin in Neonates

NCT00818584
View directory record Official record
Conditions
Candida
Interventions
Micafungin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
48 Hours to 120 Days
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
7
States / cities
Birmingham, Alabama • Orange, California • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Sep 4, 2026, 4:43 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Studies of Disorders With Increased Susceptibility to Fungal Infections

NCT01222741
View directory record Official record
Conditions
Fungal Infections, Primary Immune Deficiencies
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 85 Years
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 4, 2026, 4:43 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)

NCT03734991
View directory record Official record
Conditions
Candida Vulvovaginitis
Interventions
Ibrexafungerp, Placebo
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Sep 4, 2026, 4:43 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis

NCT03987620
View directory record Official record
Conditions
Candida Vulvovaginitis
Interventions
Ibrexafungerp, Placebo
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
21
States / cities
Mesa, Arizona • Lakewood, Colorado • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Sep 4, 2026, 4:43 PM EDT
Completed Phase 2 Interventional Results available

Suppression Of Bacterial Vaginosis (BV) [SUBVert]

NCT03930745
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Placebo, TOL-463
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Birmingham, Alabama • La Jolla, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Sep 4, 2026, 4:43 PM EDT
Completed No phase listed Observational

Retrospective Chart Review of Candida Fungemia

NCT03827330
View directory record Official record
Conditions
Candida Fungemia
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced Sep 4, 2026, 4:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Probiotic Blend Reduces Gastrointestinal Symptoms and Positively Impacts Microbiota Modulation in a Randomized Study

NCT05614726
View directory record Official record
Conditions
Microbiota, Constipation, Candida
Interventions
575mg [30 billion colony forming units] probiotic blend of Bifidobacterium breve, Lactobacillus acidophilus, Lacticaseibacillus rhamnosus, Saccharomyces boulardii, and alpha amylase
Dietary Supplement
Lead sponsor
The Center for Applied Health Sciences, LLC
Industry
Eligibility
30 Years to 60 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Canfield, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 4, 2026, 4:43 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Impact of Increased Body Mass Index on Adolescent Fixed Orthodontic Treatment. A Prospective Longitudinal Study

NCT07217756
View directory record Official record
Conditions
Obesity & Overweight, Orthodontic Treatment
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
12 Years to 18 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 4, 2026, 4:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp

NCT06954493
View directory record Official record
Conditions
Vulvovaginal Candidiasis, Candida Infection, Vaginal Candidiasis
Interventions
Ibrexafungerp
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Rogers, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Sep 4, 2026, 4:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis

NCT01926028
View directory record Official record
Conditions
Vulvovaginal Candidiasis
Interventions
NDV-3A, NDV-3, Placebo
Biological
Lead sponsor
NovaDigm Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Sep 4, 2026, 4:43 PM EDT
Completed No phase listed Observational

Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)

NCT01525095
View directory record Official record
Conditions
Candidemia
Interventions
Not listed
Lead sponsor
T2 Biosystems
Industry
Eligibility
18 Years to 95 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Birmingham, Alabama • San Francisco, California • Lexington, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Sep 4, 2026, 4:43 PM EDT
Completed Phase 2 Interventional

Itraconazole for the Prevention of Fungal Infections in Chronic Granulomatous Disease

NCT00001280
View directory record Official record
Conditions
Mycoses
Interventions
itraconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 4, 2026, 4:43 PM EDT
Completed Phase 3 Interventional

The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis

NCT00056368
View directory record Official record
Conditions
Candidiasis
Interventions
Anidulafungin, Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
King of Prussia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2008 · Synced Sep 4, 2026, 4:43 PM EDT
Completed Phase 3 Interventional Results available

Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight

NCT00734539
View directory record Official record
Conditions
Candidiasis
Interventions
fluconazole, placebo
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
2 Days to 5 Days
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
33
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Sep 4, 2026, 4:43 PM EDT
Completed No phase listed Observational

BIOPIC: Fungal Biomarkers for Diagnosis and Response to Therapy for Pediatric Candidemia

NCT02220790
View directory record Official record
Conditions
Invasive Candidiasis
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
120 Days to 18 Years
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
19
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2022 · Synced Sep 4, 2026, 4:43 PM EDT
Completed No phase listed Observational

Mucormycosis in COVID-19

NCT04935463
View directory record Official record
Conditions
Covid19, Mucormycosis, Aspergillosis, Candida Infection
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
Not listed
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 4, 2026, 4:43 PM EDT
Completed Phase 2 Interventional

RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections

NCT02733432
View directory record Official record
Conditions
Candidiasis, Vulvovaginal, Mycoses, Yeast Infection, Moniliasis, Vulvovaginal, Vaginitis, Monilial
Interventions
CD101 Vaginal Gel (3%), CD101 External gel (1%), CD101 Vaginal Ointment (6%), CD101 External ointment (1%), Fluconazole
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older · Female only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2020 · Synced Sep 4, 2026, 4:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of APX001 High-load and Low-load Tablets

NCT05491733
View directory record Official record
Conditions
Invasive Fungal Infections
Interventions
APX001, APX001A
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Sep 4, 2026, 4:43 PM EDT
Completed No phase listed Observational

PEACE: Pediatric Antifungal Comparative Effectiveness

NCT01869829
View directory record Official record
Conditions
Pediatric Invasive Candidiasis
Interventions
Observational antifungal therapy
Drug
Lead sponsor
Duke University
Other
Eligibility
120 Days to 18 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
27
States / cities
Little Rock, Arkansas • Orange, California • Palo Alto, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Sep 4, 2026, 4:43 PM EDT
Terminated Phase 3 Interventional Results available

Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis

NCT00815516
View directory record Official record
Conditions
Candidiasis
Interventions
micafungin, amphotericin B deoxycholate
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
48 Hours to 120 Days
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Orange, California • New Brunswick, New Jersey • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Sep 4, 2026, 4:43 PM EDT
Completed No phase listed Observational

Outcomes of Patients Who Fail to Respond to Fluconazole Treatment of Severe Candida Albicans Infections

NCT00721487
View directory record Official record
Conditions
Fungal Infection by Site
Interventions
Fluconazole
Drug
Lead sponsor
CPL Associates
Other
Eligibility
4 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Sep 4, 2026, 4:43 PM EDT